Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines
CAMBRIDGE, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced a three-year agreement with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the …